SCHEDULE: Armistice Capital Reports 4.99% Stake in GlucoTrack

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 102,115 shares, representing 4.99% of GlucoTrack, Inc.'s common stock, as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating their beneficial ownership of 102,115 shares of GlucoTrack, Inc. common stock.
• This holding represents 4.99% of the total class of securities.
• The filing date for this event is March 31, 2026.
• Armistice Capital, LLC is organized in Delaware, and Steven Boyd is a U.S. citizen.
• The Master Fund, an investment advisory client of Armistice Capital, has the right to receive dividends and proceeds from the sale of these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of shareholding and does not inherently signal positive or negative performance for the company.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant, though below the 5% threshold for active reporting, stake in GlucoTrack, Inc.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Negatives

• The filing does not contain any negative financial or operational information about GlucoTrack, Inc. itself, as it is a disclosure of beneficial ownership.

Risks

• While not explicitly stated as a risk in this filing, any significant change in beneficial ownership or trading activity by large holders like Armistice Capital could potentially influence market perception and stock price volatility.
• The Master Fund's right to receive dividends and sale proceeds means that strategic decisions regarding these shares may be influenced by the Master Fund's objectives.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from GlucoTrack, Inc.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual holders who acquire more than 5% of a company's stock. This filing indicates Armistice Capital's strategic interest in GlucoTrack, Inc., positioning them as a notable shareholder.

Related Party Transactions

• The Master Fund, an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

Stakeholder Impact

• Shareholders: The disclosure may influence market perception and trading activity, potentially impacting share price.
• Management of GlucoTrack, Inc.: May need to engage with or consider the interests of a significant beneficial owner.
• Investors: Provides information on who holds a notable stake in the company.

Next Steps

• Armistice Capital, LLC and Steven Boyd will be required to file amendments to this Schedule 13G if there are any material changes in their beneficial ownership.
• GlucoTrack, Inc. may see increased attention from investors due to the disclosure of a significant shareholder.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Armistice Capital, Steven Boyd, GlucoTrack, Common Stock, SEC Filing, Investment